Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that lurasidone be listed for the management of the manifestations of schizophrenia if the following clinical criteria are met:
1. Patient has a contraindication to less expensive antipsychotic agents, or
2. Patient has failed a trial of less expensive antipsychotics because of intolerance or lack of response. Indexing Status Subject indexing assigned by CRD MeSH Humans; Isoindoles; Schizophrenia; Thiazoles Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000811 Date abstract record published 17/07/2014 |